Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Peltekian

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|June 21, 2005
Review article: the changing epidemiology of hepatocellular carcinoma in CanadaZ Dyer, K Peltekian, S Veldhuyzen van Zanten
Transplantation Proceedings|June 24, 1998
Cost of liver transplantation using tacrolimusV C McAlister, K Peltekian, H Bitter-Suermann, et al.
Lancet (London, England)|February 9, 2000
Sirolimus-tacrolimus combination immunosuppressionV C McAlister, Z Gao, K Peltekian, et al.
Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada|April 16, 2003
Evaluation of Nova Scotia's hepatitis C risk notification programS G Squires, D M MacDonald, J W Scott, et al.
Journal of Viral Hepatitis|May 26, 2010
Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfectionL Barrett, M Gallant, C Howley, et al.
Communicable Disease and Public Health|July 12, 2002
Evaluation of the notification of hepatitis C risk to children who received unscreened blood or blood productsJ M Langley, S G Squires, D M MacDonald, et al.
Transplantation Proceedings|March 27, 2001
De novo use of low-dose tacrolimus and sirolimus in liver transplantationK Peltekian, V C McAlister, S Colohan, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 8, 2016
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studiesP Marotta, R Bailey, M Elkashab, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practiceS S Lee, V G Bain, K Peltekian, et al.
Advances in Experimental Medicine and Biology|October 23, 1998
Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infectionJ W Ding, Q Ning, M F Liu, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|June 21, 2005
Review article: the changing epidemiology of hepatocellular carcinoma in CanadaZ Dyer, K Peltekian, S Veldhuyzen van Zanten
Transplantation Proceedings|June 24, 1998
Cost of liver transplantation using tacrolimusV C McAlister, K Peltekian, H Bitter-Suermann, et al.
Lancet (London, England)|February 9, 2000
Sirolimus-tacrolimus combination immunosuppressionV C McAlister, Z Gao, K Peltekian, et al.
Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada|April 16, 2003
Evaluation of Nova Scotia's hepatitis C risk notification programS G Squires, D M MacDonald, J W Scott, et al.
Journal of Viral Hepatitis|May 26, 2010
Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfectionL Barrett, M Gallant, C Howley, et al.
Communicable Disease and Public Health|July 12, 2002
Evaluation of the notification of hepatitis C risk to children who received unscreened blood or blood productsJ M Langley, S G Squires, D M MacDonald, et al.
Transplantation Proceedings|March 27, 2001
De novo use of low-dose tacrolimus and sirolimus in liver transplantationK Peltekian, V C McAlister, S Colohan, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 8, 2016
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studiesP Marotta, R Bailey, M Elkashab, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practiceS S Lee, V G Bain, K Peltekian, et al.
Advances in Experimental Medicine and Biology|October 23, 1998
Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infectionJ W Ding, Q Ning, M F Liu, et al.
Pageof 2